Drug Approval | April 17, 2026
Morepen Laboratories secures fourth consecutive USFDA ‘NIL 483’ inspection
Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions
Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions
The CE Mark builds on the company’s ISO 13485 certification, further strengthening confidence in the platform's safety, quality and performance
Collaboration aims to align hospital staff learning with NABH 6th Edition standards, patient safety, and measurable quality outcomes
The goal is to better support drug developers as programs move from laboratory research into clinical trials
New Yamuna Vihar facility to train 40 students annually through diploma-led, hands-on renal care education
CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing
Strategic expansion strengthens CDMO’s support for biotech and pharma innovators across the Asia-Pacific region
_256_384.jpg)
Effective recovery at home begins with well-defined care plans that outline treatment protocols, recovery milestones, and monitoring requirements tailored to individual patient needs
The three-day conference is expected to bring together more than 3,000 physiotherapists, clinicians, researchers, academicians, and students
The event also featured discussions on emerging trends in joint replacement surgery
Subscribe To Our Newsletter & Stay Updated
